Save Product
Product Details
- Genetically modified cell lines best reflect MOA (Mechanism of Action)
- Higher activity and larger assay window for robust and reproducible cell-based bioassay
- Comprehensive application data to support assay development and validation
- Full tracible record, stringent quality control and validated cell passage stability
- Parental cell line legally obtained from internationally recognized cell resource bank and commercially licensed
- Global commercial license assistance whenever regulatory filing is required
Description
The Human TACI (Luc) HEK293 Reporter Cell was engineered to not only express NF-κB signaling response element, but also express the receptor full length human TACI (Uniprot: O14836-1). When stimulated with human APRIL or BAFF protein, receptor-mediated signaling can drive NF-κB-mediated luminescence. Neutralization of biological effect of the ligand-receptor interaction by corresponding antibody or fusion protein results in a decrease in luminescence.
Application
• Screen for neutralizing antibodies or fusion proteins blocking the stimulation of human APRIL or BAFF protein.
Growth Properties
Adherent
Selection Marker
Puromycin (2 μg/mL) + Hygromycin (20 μg/mL)
Complete Growth Medium
DMEM + 10% FBS
Freeze Medium
Serum-free cell cryopreservation medium
Quantity
1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium
Storage
Frozen in liquid nitrogen.
Mycoplasma Testing
Negative
Sterility Testing
Negative
Instructions for Use
See data sheet for detailed culturing and assay protocol.
ACRO Quality Management System
Customers Also Viewed
Performance Data
Application
Inhibition of human APRIL protein-induced reporter activity by human BAFF and APRIL dual inhibitor.
The Human TACI (Luc) HEK293 Reporter Cell was incubated with serial dilutions of inhibitors in the presence of human APRIL protein (Cat. No. APL-H52D1) with a final concentration of 0.1 μg/mL. The EC50 of Telitacicept is approximately 0.6725 μg/mL, The EC50 of Atacicept is approximately 0.5629 μg/mL.Protocol
Inhibition of human BAFF protein-induced reporter activity by human BAFF and APRIL dual inhibitor.
The Human TACI (Luc) HEK293 Reporter Cell was incubated with serial dilutions of inhibitors in the presence of human BAFF protein (Cat. No. BAF-H52D4) with a final concentration of 0.3 μg/mL. The EC50 of Telitacicept is approximately 0.1883 μg/mL. The EC50 of Atacicept is approximately 0.1956 μg/mL.Protocol
Signaling Bioassay
Response to human APRIL protein (RLU).
The Human TACI (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human APRIL protein (Cat. No. APL-H52D1). The EC50 was approximately 0.1169 μg/mL.Protocol
Response to human APRIL protein (FOLD).
The Human TACI (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human APRIL protein (Cat. No. APL-H52D1). The max induction fold was approximately 11.81.Protocol
Response to human BAFF protein (RLU).
The Human TACI (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human BAFF protein (Cat. No. BAF-H52D4). The EC50 was approximately 0.2826 μg/mL.Protocol
Response to human BAFF protein (FOLD).
The Human TACI (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human BAFF protein (Cat. No. BAF-H52D4). The max induction fold was approximately 13.74.Protocol
Passage Stability
Passage stability analysis by Signaling Bioassay.
The continuously growing Human TACI (Luc) HEK293 Reporter Cell was stimulated with serial dilutions of human BAFF protein. Human BAFF protein stimulated response demonstrates passage stabilization (fold induction and EC50) across passage 6-21.Protocol
Customer Reviews Writing Reviews
Important Statement
Limited Use&License Disclosure
BY USE OF THIS PRODUCT, RESEARCHER AGREES TO BE BOUND BY THE FOLLOWING TERMS OF LIMITED USE OF THIS CELL LINE PRODUCT.
- If the researcher is not willing to accept the terms of limited use of this cell line product, and the product is unused, ACRO will accept return of the unused product.
- Researchers may use this product for research use only, no commercial use is allowed. "Commercial use" means any and all uses of this product and derivatives by a party for profit or other consideration and may include but is not limited to use in: (1) product manufacture; and (2) to provide a service, information or data; and/or resale of the product or its derivatives, whether or not such product or derivatives are resold for use in research.
- This cell line is neither intended for any animal or human therapeutic purposes nor for any direct human in vivo use. You have no right to share, modify, transfer, distribute, sell, sublicense, or otherwise make the cell line available for use to other researchers, laboratories, research institutions, hospitals, universities, or service organizations.
- ACROBIOSYSTEMS MAKES NO WARRANTIES OR REPRESENTATIONS OF ANY KIND, EITHER EXPRESSED OR IMPLIED, WITH RESPECT TO THE SUITABILITY OF THE CELL LINE FOR ANY PARTICULAR USE.
- ACROBIOSYSTEMS ACCEPTS NO LIABILITY IN CONNECTION WITH THE HANDLING OR USE OF THE CELL LINE.
- Modifications of the cell line, transfer to a third party, or commercial use of the cell line may require a separate license and additional fees. Please contact order@acrobiosystems.com for further details.
Recent Advances
Drug Development Progress- English Name：
Tumor necrosis factor receptor superfamily member 13B
- Category：
- Approved Drugs：
0 Details
- Drugs in Clinical Trials：
0 Details
- Highest Development Stage：
Preclinical
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing
